Aggressive locoregional management of recurrent peritoneal sarcomatosis. Issue 4 (5th February 2013)

• Record Type: Journal Article
• Authors: Baumgartner, Joel M.; Ahrendt, Steven A.; Pingpank, James F.; Holtzman, Matthew P.; Ramalingam, Lekshmi; Jones, Heather L.; Zureikat, Amer H.; Zeh, Herbert J.; Bartlett, David L.; Choudry, Haroon A.
• Is Part Of: Journal of surgical oncology. Volume 107:Issue 4(2013:Mar. 15)
• Page Start: 329
• Page End: 334
• Publication Date: 2013-02-05
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23232
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="abs1-1" sec-type="section"> <title>Background</title> <p>and Objectives Peritoneal sarcomatosis responds poorly to systemic chemotherapy and demonstrates high rates of recurrence after resection. We sought to determine perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for recurrent sarcomatosis.</p> </sec> <sec id="abs1-2" sec-type="section"> <title>Methods</title> <p>We reviewed 15 patients undergoing 17 CRS/HIPEC for recurrent sarcomatosis from a prospective database.</p> </sec> <sec id="abs1-3" sec-type="section"> <title>Results</title> <p>There were four synovial cell sarcomas, five liposarcomas, three leiomyosarcomas, two gastrointestinal stromal tumors (GIST), and three other sarcomas. Adequate cytoreduction (CC‐0/1) was achieved in all patients, with a median intra‐operative Simplified Peritoneal Carcinomatosis Index of 6 (range: 3–9). Median blood loss and operative time were 1 L (range: 450–5, 200) and 402 min (range: 324–680), respectively. Chemoperfusion drug was mitomycin C, cisplatin, or doxorubicin. Significant post‐operative complications (Clavien–Dindo III/IV) occurred in four (24%) patients, with no 60‐day mortalities and three (18%) 60‐day re‐admissions. Median intra‐abdominal disease‐free and overall survival after CRS/HIPEC was 17.2 (95% CI: 2.4–19.7 months) and 22.6 months (95% CI: 6.1–62.6 months), respectively. There was a trend towards delayed recurrence after combined CRS/HIPEC than after prior CRS alone (17.2 months vs. 10.7 months, respectively; <italic>P</italic> = 0.52).</p> </sec> <sec id="abs1-4" sec-type="section"> <title>Conclusion</title> <p>Cytoreduction combined with HIPEC may improve loco‐regional disease control in patients with recurrent sarcomatosis. J. Surg. Oncol. 2013;107:329–334. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>